Ention of new NMSC on the face and ears.98 IMIQUIMOD Imiquimod stimulates innate and cell-mediated immune response, potentiating their anti-viral, anti-tumor and immunoregulatory.

Imiquimod cream 5% ises Opioid Receptor up to 100 percent. Patterns of imiquimod applications h Frequently have been associated with better responses in combination. Once are daily application, groups or 5x/wk had the h Chsten rates of efficacy with acceptable safety profiles.148, 149 h Ufigsten adverse events included local skin reactions. In RCTs evaluating a total of 890 patients with histologically confirmed BCC with re U treatment with imiquimod 5% cream or 5x/wk 7x/wk for six weeks or placebo, 145 150, has been shown that imiquimod treatment groups received much better clinical and histological.
Local skin reactions were h More frequently in the 7 x / week in the imiquimod-treated group 5x/wk reported. Nodule Re basal cell carcinoma. In two phase 2 Fulvestrant studies the h HIGHEST response rate was 76 percent with imiquimod 5% cream twice t Possible for 12 weeks.151 The answers to these studies were not as high as that observed in studies in which BCC with imiquimod treated cream 5%. This type of therapy is best for those patients for whom surgery, radiation or cryotherapy is not an option applied. In one RCT, 93 patients with histologically proven applied imiquimod 5% cream 152 NBCC in various schemes for six weeks. at the end of treatment, h ufigere applications under occlusion did better than the less hours ufigen applications, however, no significant difference between groups was observed.
A systematic review of the evidence on the basis supports the use of imiquimod as a single agent for BCC and SCC in situ. The use of this modality T can, for patients with small tumors in low risk areas that are not operated on k Can or other treatment processes in which the long-term Zinss Tze of clearance were determined.153 resiquimod limited to resiquimod TLR agonists is a 7/8, the effects similar to those of imiquimod has on monocytes, although it is 10 to 100 times st stronger than imiquimod.154 156 thus induces an IL-1 receptor antagonist, is granulocytecolony stimulating factor, granulocyte-colony -factor macrophages, macrophage inflammatory protein MIP 1 and monocyte chemotactic protein.
156 A total of 132 patients from April to August KA on the face or balding scalp in different concentrations of resiquimod once received 3x/wk per day for four weeks completely requests reference requests getting responses from 40 applied, 0 to 74.2 percent . No statistically significant difference was found between the different concentrations of resiquimod, but was better reps Opportunity with less observed concentrations.157 MEBUTATE ingenol mebutate ingenol is an extract from the plant Euphorbia peplus, also known as milkweed, which was used for several years as home remedies for skin disorders such as actinic keratoses and skin cancers.158 161 It has a dual mechanism causes chemical ablation first, and the effects of the plasma membrane of the loss of mitochondrial membrane potential and mitochondrial swelling, especially in dysplastic keratinocytes, leading to rapid cell death by necrosis prime r. It also induces a rapid recovery and restoration of normal clinical and histological necrosis morphology.158 This makes Glicht IM to remaining